إيميداكلوبريد

For the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs. Kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis). For the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis. It is also indicated for the treatment and control of the following intestinal parasites: adult, immature adult and fourth stage larvae in hookworm species (Ancylostoma caninum and Uncinaria stenocephala); adult and fourth stage larvae in roundworm species (Toxocara canis); and adult stage in roundworm species (Toxascaris leonina) and whipworm (Trichuris vulpis).

PARASEDGE® Multi for Dogs

For the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs; kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis); for the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis; and for the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis).

Midamox® for Dogs

For the prevention of heartworm disease caused by Dirofilaria immitis; and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs; and the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis); kills adult fleas and treats flea infestations (Ctenocephalides felis); treats and controls sarcoptic mange caused by Sarcoptes scabiei var. canis.

Do not administer this product orally. For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals. Federal Law restricts this drug to use by or on the order of a licensed veterinarian. Do not use this product (containing 2.5 %moxidectin) on cats.

Advantage Multi™ for Dogs

For the prevention of heartworm disease caused by Dirofilaria immitis; kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis).

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Advantage® DUO

advantus™ kills adult fleas and is indicated for the treatment of flea infestations on dogs and puppies 10 weeks of age and older and weighing 4 pounds or greater.

Do not give to puppies younger than 10 weeks of age or to dogs weighing less than 4 pounds. Do not give more than one tablet a day.

advantus™

For the prevention of heartworm disease caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. It is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations and the following intestinal parasites: adult, immature adult, and fourth stage larvae in hookworms (Ancyclostoma tubaeforme); and adult and fourth stage larvae in roundworms (Toxacara cati).

PARASEDGE™ Multi for Cats

For the prevention of heartworm disease caused by Dirofilaria immitis; kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. It is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations, intestinal roundworms (Toxocara cati), and hookworms (Ancylostoma tubaeforme).

Midamox® for Cats

For the prevention of heartworm disease caused by Dirofilaria immitis; for the treatment and control of ear mite (Otodectes cynotis) infestations, intestinal roundworms (Toxocara cati), and hookworms (Ancylostoma tubaeforme); kills adult fleas and treats flea infestations (Ctenocephalides felis).

Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian. Do not use on sick, debilitated, or underweight cats. Do not use on cats less than 9 weeks of age or less than 2 lbs. body weight. Do not apply to irritated skin.

advantage multi™ for cats

For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis; kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets.

Use only the 0.4 mL ADVANTAGE MULTI for Cats in ferrets. The 0.23 mL size does not provide an effective dose and the 0.8mL size could result in an overdose. Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian. Do not use on sick or debilitated ferrets. Do not apply to irritated skin.

advantage multi™ for cats

IMOXI™ Topical Solution for Dogs is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs. IMOXI™ Topical Solution for Dogs kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis). IMOXI™ Topical Solution for Dogs is indicated for the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis. IMOXI™ Topical Solution for Dogs is also indicated for the treatment and control of the following intestinal parasites: Intestinal Parasite Intestinal Stage Adult Immature Adult Fourth Stage Larvae Hookworm Species Ancylostoma caninum X X X Uncinaria stenocephala X X X Roundworm Species Toxocara canis X X Toxascaris leonina X Whipworm Trichuris vulpis X

IMOXI™ Topical Solution for Dogs (imidacloprid + moxidectin)

INDICATIONS: IMOXI™ Topical Solution for Cats is indicated for the prevention of heartworm disease caused by Dirofilaria immitis. IMOXI™ Topical Solution for Cats kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. IMOXI™ Topical Solution for Cats is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations and the following intestinal parasites: Intestinal Parasite Intestinal Stage Adult Immature Adult Fourth Stage Larvae Hookworm Species Ancylostoma tubaeforme X X X Roundworm Species Toxocara cati X X

IMOXI™ Topical Solution for Cats (imidacloprid + moxidectin)

PARASEDGE™ Multi for Dogs is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs. PARASEDGE™ Multi for Dogs kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis).PARASEDGE™ Multi for Dogs is indicated for the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis.PARASEDGE™ Multi for Dogs is also indicated for the treatment and control of the following intestinal parasites:

PARASEDGE™ Multi for Dogs(imidacloprid + moxidectin) Topical Solution

103963B Once-a-month topical solution for the prevention of heartworm disease, the treatment of circulating microfilariae, kills adult fleas, is indicated for the treatment of flea infestations, the treatment and control of sarcoptic mange, as well as the treatment and control of intestinal parasite infections in dogs and puppies that are at least 7 weeks of age and that weigh at least 3 lbs.

IMOXI™ Topical Solution for Dogs (imidacloprid + moxidectin)

PARASEDGE™ Multi for Cats is indicated for the prevention of heartworm disease caused by Dirofilaria immitis. PARASEDGE™ Multi for Cats kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. PARASEDGE™ Multi for Cats is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations and the following intestinal parasites:

PARASEDGE™ Multi for Cats(imidacloprid + moxidectin)Topical Solution

Once-a-month topical solution for cats for the prevention of heartworm disease, kills adult fleas, is indicated for the treatment of flea infestations, as well as the treatment and control of ear mite infestations and intestinal parasite infections in cats and kittens 9 weeks of age and older and that weigh at least 2 lbs.

IMOXI™ Topical Solution for Cats (imidacloprid + moxidectin)

For ferrets: PARASEDGE Multi for Cats is indicated for the prevention of heartworm disease in ferrets caused by Dirofilaria immitis. PARASEDGE Multi for Cats kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets.

PARASEDGE™ Multi for Cats(imidacloprid + moxidectin)Topical Solution

advantus kills adult fleas and is indicated for the treatment of flea infestations on dogs and puppies 10 weeks of age and older and weighing 4 pounds or greater.

advantusTM (imidacloprid) soft chew

Do not administer this product orally. (See WARNINGS.) Do not use this product (containing 2.5 % moxidectin) on cats.

PARASEDGE™ Multi for Dogs(imidacloprid + moxidectin) Topical Solution

HUMAN WARNINGS: Not for human use. Keep out of the reach of children. Children should not come in contact with the application site for 30 minutes after application. Causes eye irritation. Harmful if swallowed. Do not get in eyes or on clothing. Avoid contact with skin. Exposure to the product has been reported to cause headache; dizziness; and redness, burning, tingling, or numbness of the skin. Wash hands thoroughly with soap and warm water after handling. If contact with eyes occurs, hold eyelids open and flush with copious amounts of water for 15 minutes. If eye irritation develops or persists, contact a physician. If swallowed, call poison control center or physician immediately for treatment advice. Have person sip a glass of water if able to swallow. Do not induce vomiting unless told to do so by the poison control center or physician. People with known hypersensitivity to benzyl alcohol, imidacloprid or moxidectin should administer the product with caution. In case of allergic reaction, contact a physician. If contact with skin or clothing occurs, take off contaminated clothing. Wash skin immediately with plenty of soap and water. Call a poison control center or physician for treatment advice. The Safety Data Sheet (SDS) provides additional occupational safety information. To report suspected adverse drug events, for technical assistance or to obtain a copy of the SDS, contact Vetoquinol USA at 1-800-835-9496 or www.vetoquinolusa.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.

IMOXI™ Topical Solution for Cats (imidacloprid + moxidectin)

Not for human use. Keep out of the reach of children. Children should not come in contact with application sites for two (2) hours after application. Causes eye irritation. Harmful if swallowed. Do not get in eyes or on clothing. Avoid contact with skin. Exposure to the product has been reported to cause headache; dizziness; and redness, burning, tingling, or numbness of the skin. Wash hands thoroughly with soap and warm water after handling. If contact with eyes occurs, hold eyelids open and flush with copious amounts of water for 15 minutes. If eye irritation develops or persists, contact a physician. If swallowed, call poison control center or physician immediately for treatment advice. Have person sip a glass of water if able to swallow. Do not induce vomiting unless told to do so by the poison control center or physician. People with known hypersensitivity to benzyl alcohol, imidacloprid or moxidectin should administer the product with caution. In case of allergic reaction, contact a physician. If contact with skin or clothing occurs, take off contaminated clothing. Wash skin immediately with plenty of soap and water. Call a poison control center or physician for treatment advice. The Safety Data Sheet (SDS) provides additional occupational safety information. For product questions, to report adverse reactions, or for a copy of the Safety Data Sheet (SDS), call Elanco Product & Veterinary Support at 888-545-5973.

Elanco TM advantage multi™ for dogs (imidacloprid+moxidectin) Topical Solution

For the first 30 minutes after application: Ensure that dogs cannot lick the product from application sites on themselves or other treated dogs, and Separate treated dogs from one another and from other pets to reduce the risk of accidental ingestion. Ingestion of this product by dogs may cause serious adverse reactions including depression, salivation, dilated pupils, incoordination, panting, and generalized muscle tremors. In avermectin sensitive dogs, a the signs may be more severe and may include coma and death. b a Some dogs are more sensitive to avermectins due to a mutation in the MDR1 gene. Dogs with this mutation may develop signs of severe avermectin toxicity if they ingest this product. The most common breeds associated with this mutation include Collies and Collie crosses. b Although there is no specific antagonist for avermectin toxicity, even severely affected dogs have completely recovered from avermectin toxicity with intensive veterinary supportive care.

Midamox® for Dogs(imidacloprid + moxidectin)Topical Solution

Not for human use. Keep this and all drugs out of reach of children. Keep advantus in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

advantusTM (imidacloprid) soft chew

WARNINGS: Do not use on sick, debilitated, or underweight cats (see ADVERSE REACTIONS). Do not use on cats less than 9 weeks of age or less than 2 lbs. body weight.

IMOXI™ Topical Solution for Cats (imidacloprid + moxidectin)

Do not use on sick or debilitated ferrets.

PARASEDGE™ Multi for Cats(imidacloprid + moxidectin)Topical Solution

Heartworm-Negative Dogs Field Studies: Following treatment with imidacloprid and moxidectin topical solution or an active control, dog owners reported the following post-treatment reactions: During a field study using 61 dogs with pre-existing flea allergy dermatitis, one (1.6%) dog experienced localized pruritus immediately after imidacloprid application, and one investigator noted hyperkeratosis at the application site of one dog (1.6%). In a field safety and effectiveness study, imidacloprid and moxidectin topical solution was administered to 92 client-owned dogs with sarcoptic mange. The dogs ranged in age from 2 months to 12.5 years and ranged in weight from 3 to 231.5 pounds. Adverse reactions in dogs treated with imidacloprid and moxidectin topical solution included hematochezia, diarrhea, vomiting, lethargy, inappetence, and pyoderma. Laboratory Effectiveness Studies: One dog in a laboratory effectiveness study experienced weakness, depression, and unsteadiness between 6 and 9 days after application with imidacloprid and moxidectin topical solution. The signs resolved without intervention by day 10 post-application. The signs in this dog may have been related to peak serum levels of moxidectin, which vary between dogs, and occur between 1 and 21 days after application of imidacloprid and moxidectin topical solution. The following clinical observations also occurred in laboratory effectiveness studies following application with imidacloprid and moxidectin topical solution and may be directly attributed to the drug or may be secondary to the intestinal parasite burden or other underlying conditions in the dogs: diarrhea, bloody stools, vomiting, anorexia, lethargy, coughing, ocular discharge and nasal discharge. Observations at the application sites included damp, stiff or greasy hair, the appearance of a white deposit on the hair, and mild erythema, which resolved without treatment within 2 to 48 hours. Heartworm-Positive Dogs Field Study: A 56-day field safety study was conducted in 214 D. immitis heartworm and microfilaria positive dogs with Class 1, 2 or 3 heartworm disease. All dogs received imidacloprid and moxidectin topical solution on Study Days 0 and 28; 108 dogs also received melarsomine dihydrochloride on Study Days -14, 14 and 15. All dogs were hospitalized for a minimum of 12 hours following each treatment. Effectiveness against circulating D. immitis microfilariae was > 90% at five of six sites; however, one site had an effectiveness of 73.3%. The microfilaria count in some heartworm-positive dogs increased or remained unchanged following treatment with imidacloprid and moxidectin topical solution alone or in a dosing regimen with melarsomine dihydrochloride. Following treatment with imidacloprid and moxidectin topical solution alone or in a dosing regimen with melarsomine dihydrochloride, the following adverse reactions were observed: Three dogs treated with imidacloprid and moxidectin topical solution ina dosing regimen with melarsomine dihydrochloride died of pulmonary embolism from dead and dying heartworms. One dog, treated with imidacloprid and moxidectin topical solution and melarsomine dihydrochloride, experienced pulmonary hemorrhage and responded to supportive medical treatment. Following the first treatment with imidacloprid and moxidectin topical solution alone, two dogs experienced adverse reactions (coughing, vomiting, and dyspnea) that required hospitalization. In both groups, there were more adverse reactions to imidacloprid and moxidectin topical solution following the first treatment than the second treatment. To report a suspected adverse reaction, call 1-800-338-3659. Post-Approval Experience The following adverse events are based on post-approval adverse drug experience reporting. Not all adverse reactions are reported to FDA CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using this data. The following adverse events in dogs are listed in decreasing order of reporting frequency: depression/lethargy, vomiting, pruritus, diarrhea, anorexia, hyperactivity, ataxia, trembling, hypersalivation, application site reactions (alopecia, pruritus, lesions, and erythema), seizures, and anaphylaxis/anaphylactic reactions (hives, urticaria, facial swelling, edema of the head). Serious reactions, including neurologic signs and death have been reported when cats have been exposed (orally and topically) to this product. In humans, nausea, numbness or tingling of the mouth/lips and throat, ocular and dermal irritation, pruritus, headache, vomiting, diarrhea, depression and dyspnea have been reported following exposure to this product. To report suspected adverse events and/or obtain a copy of the SDS or for technical assistance, call VIRBAC AH, Inc. at 1-800-338-3659. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/reportanimalae.

PARASEDGE™ Multi for Dogs(imidacloprid + moxidectin) Topical Solution

Field Study: Following treatment with imidacloprid and moxidectin or an active control, cat owners reported the following post-treatment reactions: During another field study, a 16-year-old cat with renal disease slept in the same place without moving for two days following application. (See PRECAUTIONS.) Laboratory Effectiveness Studies: Imidacloprid and moxidectin was administered at the recommended dose to 215 cats in 20 effectiveness studies. One random-sourced cat exhibited signs consistent with either moxidectin toxicity or viral respiratory disease and died 26 hours after product application; necropsy findings were inconclusive as to the cause of death. A second cat that became ill 3 days after application of imidacloprid and moxidectin responded to treatment for respiratory infection and completed the study. A third cat became ill on day 3 and died with signs and lesions attributable to panleukopenia on day 7 after moxidectin application. Post-approval Experience: The following adverse events are based on post approval adverse drug experience reporting. Not all adverse reactions are reported to FDA CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using this data. The following adverse events in cats are listed in decreasing order of reporting frequency: hypersalivation, depression/lethargy, application site reactions (alopecia, pruritus, lesions, and erythema), decreased appetite, vomiting, hyperactivity, ataxia, trembling, and behavior disorder (hiding). In some cases death has been reported. In humans, ocular and dermal irritation, nausea, numbness or tingling of the mouth and lips, anaphylaxis, pruritus, vomiting, and tongue/taste abnormalities have been reported following exposure to this product. To report suspected adverse events and/or obtain a copy of the SDS or for technical assistance, call VIRBAC AH, Inc. at 1-800-338-3659. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/reportanimalae.

PARASEDGE™ Multi for Cats(imidacloprid + moxidectin)Topical Solution

Field Safety Study in Ferrets: Imidacloprid and moxidectin was topically administered to 131 client-owned ferrets at the recommended dose volume (0.4 mL). The ferrets ranged in age from 3 months to 7 years, and weighed between 0.5 and 1.86 kg (1.1 to 4.1 lbs). The dose of imidacloprid ranged between 21.5 to 80.2 mg/kg in this study. The dose of moxidectin ranged between 2.2 to 8.0 mg/kg in this study. Adverse reactions in ferrets following treatment included: pruritus/scratching, scabbing, redness, wounds and inflammation at the treatment site; lethargy; and chemical odor. These adverse reactions resolved without additional therapy. Owners also reported stiffening of the hair at the treatment site, however, this is expected with application of a topical product and is not considered an adverse reaction. Three human adverse reactions were reported. An owner’s finger became red following skin contact with the product. One owner reported a headache caused by the chemical odor of the product. One owner reported a tingling sensation of the lips after kissing the treatment site. Foreign Market Experience: Because the following events were reported voluntarily during post-approval use of the product in foreign markets, it is not always possible to reliably establish a causal relationship to drug exposure. Adverse events reported in ferrets topically treated with 0.4 mL imidacloprid + moxidectin for cats included: malaise, vomiting, diarrhea, shaking, mydriasis, hypersalivation with abnormal neurologic signs, seizures, death, generalized hematoma of the body, and alopecia at the treatment site. Adverse reactions in humans included: burning, tingling, numbness, bad taste in the mouth, dizziness, and headache.

PARASEDGE™ Multi for Cats(imidacloprid + moxidectin)Topical Solution

Side effects seen with this drug include vomiting, decreased appetite, decreased energy, soft stools and difficulty walking.

advantusTM (imidacloprid) soft chew

ADVERSE REACTIONS:

IMOXI™ Topical Solution for Cats (imidacloprid + moxidectin)

The recommended minimum dosage is 4.5 milligram per pound (10 milligram per kilogram) of imidacloprid and 36.4 micrograms per pound (80 micrograms per kilogram) of ivermectin, topically once a month.

Topical

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Advantage® DUO

The recommended minimum dose is 4.5 mg/lb. (10 mg/kg) imidacloprid and 1.1 mg/lb. (2.5 mg/kg) moxidectin, once a month, by topical administration.

Topical

IMOXI™ Topical Solution for Dogs

Administer daily one 7.5-mg chew to dogs weighing 4 to 22 pounds or one 37.5-mg chew to dogs weighing 23 to 110 pounds.

Oral

Do not give to puppies younger than 10 weeks of age or to dogs weighing less than 4 pounds. Do not give more than one tablet a day.

advantus™

Apply 4.5 mg/lb body weight (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg)moxidectin, once a month.

Topical

Do not administer this product orally. For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals. Federal Law restricts this drug to use by or on the order of a licensed veterinarian. Do not use this product (containing 2.5 %moxidectin) on cats.

Advantage Multi™ for Dogs

The recommended minimum dose for a ferret is 9 mg/lb (20 mg/kg) imidacloprid and 0.9 mg/lb (2mg/kg) moxidectin, once a month, by topical administration. Only the 0.4 mL applicator volume (Midamox 9) should be used on ferrets.

Topical

Midamox® for Cats

9 mg/lb (20 mg/kg) imidacloprid and 0.9 mg/lb (2 mg/kg) moxidectin, once a month, by topical administration. Only the 0.4 mL applicator tube volume (PARASEDGE™ Multi 9) should be used on ferrets.

Topical

PARASEDGE™ Multi for Cats

The recommended minimum dose for a ferret is 9 m/lb (20 mg/kg) imidacloprid and 0.9 mg/lb (2 mg/kg) moxidectin, once a month, by topical administration.

Topical

Barrier® for cats

The recommended minimum dose is 4.5 mg/lb. (10.0 mg/kg) imidacloprid and 0.45 mg/lb. (1.0 mg/kg) moxidectin, once a month, by topical administration.

Topical

IMOXI™ Topical Solution for Cats

Apply 4.5 mg/lb body weight (10 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin, once a month.

Topical

Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian. Do not use on sick, debilitated, or underweight cats. Do not use on cats less than 9 weeks of age or less than 2 lbs. body weight. Do not apply to irritated skin.

advantage multi™ for cats

The recommended minimum dose is 4.5 mg/lb (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin, once a month, by topical administration. Do not apply to irritated skin. Remove the applicator from the outer pouch using scissors or fold along diagonal line to expose nick; tear back at nick. As specified in the following table, administer the entire contents of the Midamox for Dogs (imidacloprid and moxidectin) applicator that correctly corresponds with the body weight of the dog. * Dogs over 110 lbs. should be treated with the appropriate combination of Midamox for Dogs applicators. Dog (lbs.) Midamox for Dogs Volume (mL) Imidacloprid (mg) Moxidectin (mg) 3–9 Midamox 9 0.4 40 10 9.1–20 Midamox 20 1.0 100 25 20.1–55 Midamox 55 2.5 250 62.5 55.1–88 Midamox 88 4.0 400 100 88.1–110* Midamox 110 5.0 500 125 Hold the applicator upright. Tap the narrow part of the applicator to ensure the contents remain within the main body of the applicator. Twist or snap back the tip. The dog should be standing for application. Part the hair on the back of the dog between the shoulder blades until the skin is visible. For dogs weighing 20 lbs. or less, place the tip of the applicator on the skin and apply the entire contents directly on the exposed skin at one spot between the shoulder blades. For dogs weighing more than 20 lbs., place the tip of the applicator on the skin and apply the entire contents directly on the exposed skin at 3 or 4 spots on the top of the backline from the base of the neck to the upper back in an area inaccessible to licking. Do not apply an amount of solution at any one location that could run off the side of the dog. Do not let this product get in your dog's mouth or eyes. Do not allow the dog to lick any of the application sites for 30 minutes. In households with multiple pets, keep each treated dog separated from other treated dogs and other pets for 30 minutes after application to prevent licking the application sites. (See WARNINGS.) Contact with eyes can lead to eye irritation and corneal ulceration. If contact with eyes occurs, hold the dog's eyelids open, flush thoroughly with water, and contact your veterinarian. Stiff hair, a damp appearance of the hair, pink skin, or a slight powdery residue may be observed at the application site on some animals. This is temporary and does not affect the safety and effectiveness of the product. Shampooing 90 minutes after treatment does not reduce the effectiveness of Midamox for Dogs in the prevention of heartworm disease. Shampooing or water immersion 4 days after treatment will not reduce the effectiveness of Midamox for Dogs in the treatment of flea infestations. However, shampooing as often as once weekly may reduce the effectiveness of the product against fleas. Heartworm Prevention: For prevention of heartworm disease, Midamox for Dogs should be administered at one-month intervals. Midamox for Dogs may be administered year-round or at a minimum should start one month before the first expected exposure to mosquitoes and should continue at monthly intervals until one month after the last exposure to mosquitoes. If a dose is missed and a 30-day interval between doses is exceeded, administer Midamox for Dogs immediately and resume the monthly dosing schedule. When replacing another heartworm preventative product in a heartworm prevention program, the first treatment with Midamox for Dogs should be given within one month of the last dose of the former medication. Treatment of Circulating Microfilaria: For the treatment of circulating D. immitis microfilaria in heartworm-positive dogs, Midamox for Dogs should be administered at one-month intervals. Treatment with an approved adulticide therapy is recommended because Midamox for Dogs is not effective for the treatment of adult D. immitis. (See PRECAUTIONS.)

TOPICAL

Midamox® for Dogs(imidacloprid + moxidectin)Topical Solution

The recommended minimum dose is 4.5 mg/lb (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin, once a month, by topical administration. Do not apply to irritated skin. Do not let this product get in your dog’s mouth or eyes. Do not allow the dog to lick any of the application sites for 30 minutes. In households with multiple pets, keep each treated dog separated from other treated dogs and other pets for 30 minutes after application to prevent licking the application sites. (See WARNINGS.) Stiff hair, a damp appearance of the hair, pink skin, or a slight powdery residue may be observed at the application site on some animals. This is temporary and does not affect the safety and effectiveness of the product. Shampooing 90 minutes after treatment does not reduce the effectiveness of PARASEDGE™ Multi for Dogs in the prevention of heartworm disease. Shampooing or water immersion 4 days after treatment will not reduce the effectiveness of PARASEDGE™ Multi for Dogs in the treatment of flea infestations. However, shampooing as often as once weekly may reduce the effectiveness of the product against fleas. Heartworm Prevention: For prevention of heartworm disease, PARASEDGE™ Multi for Dogs should be administered at one-month intervals. PARASEDGE™ Multi for Dogs may be administered year-round or at a minimum should start one month before the first expected exposure to mosquitoes and should continue at monthly intervals until one month after the last exposure to mosquitoes. If a dose is missed and a 30-day interval between doses is exceeded, administer PARASEDGE™ Multi for Dogs immediately and resume the monthly dosing schedule. When replacing another heartworm preventative product in a heartworm prevention program, the first treatment with PARASEDGE™ Multi for Dogs should be given within one month of the last dose of the former medication. Treatment of Circulating Microfilaria: For the treatment of circulating D. immitis microfilaria in heartworm-positive dogs, PARASEDGE™ Multi for Dogs should be administered at one-month intervals. Treatment with an approved adulticide therapy is recommended because PARASEDGE™ Multi for Dogs is not effective for the treatment of adult D. immitis. (See PRECAUTIONS.) Flea Treatment: For the treatment of flea infestations, PARASEDGE™ Multi for Dogs should be administered at one-month intervals. If the dog is already infested with fleas when the first dose of PARASEDGE™ Multi for Dogs is administered, adult fleas on the dog will be killed. However, reinfestation from the emergence of pre-existing pupae in the environment may continue to occur for six weeks or longer after treatment is initiated. Dogs treated with imidacloprid, including those with pre-existing flea allergy dermatitis have shown clinical improvement as a direct result of elimination of fleas from the dog. Treatment and Control of Intestinal Nematode Infections: For the treatment and control of intestinal hookworm infections caused by Ancylostoma caninum and Uncinaria stenocephala (adults, immature adults and fourth stage larvae) and roundworm infections caused by Toxocara canis (adults and fourth stage larvae), and Toxascaris leonina (adults), and whipworm infections caused by Trichuris vulpis (adults), PARASEDGE™ Multi for Dogs should be administered once as a single topical dose. Treatment and Control of Sarcoptic Mange: For the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis, PARASEDGE™ Multi for Dogs should be administered as a single topical dose. A second monthly dose may be administered if necessary.

TOPICAL

PARASEDGE™ Multi for Dogs(imidacloprid + moxidectin) Topical Solution

The recommended minimum dose is 4.5 mg/lb (10.0 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin, once a month, by topical administration. Do not apply to irritated skin. As specified in the following table, administer the entire contents of the PARASEDGE™ Multi for Cats (10% imidacloprid + 1% moxidectin) tube that correctly corresponds with the body weight of the cat. Do not get this product in the cat’s mouth or eyes or allow the cat to lick the application site for 30 minutes. Treatment at the base of the head will minimize the opportunity for ingestion by grooming. In households with multiple pets, keep animals separated to prevent licking of the application site. Stiff, matted hair or a damp, oily appearance of the hair may be observed at the application site on some cats. This is temporary and does not affect the safety and effectiveness of the product. Heartworm Prevention: For prevention of heartworm disease, PARASEDGE™ Multi for Cats should be administered at one-month intervals. PARASEDGE™ Multi for Cats may be administered year-around or at a minimum should start one month before the first expected exposure to mosquitoes and should continue at monthly intervals until one month after the last exposure to mosquitoes. If a dose is missed and a 30-day interval between doses is exceeded, administer PARASEDGE™ Multi for Cats immediately and resume the monthly dosing schedule. When replacing another heartworm preventative product in a heartworm prevention program, the first treatment with PARASEDGE™ Multi for Cats should be given within one month of the last dose of the former medication. At the discretion of the veterinarian, cats older than 6 months of age may be tested to determine the presence of existing heartworm infection before treatment with PARASEDGE™ Multi for Cats (See ADVERSE REACTIONS Post-Approval Experience). Flea Treatment: For the treatment of flea infestations, PARASEDGE™ Multi for Cats should be administered at one-month intervals. If the cat is already infested with fleas when the first dose of PARASEDGE™ Multi for Cats is administered, adult fleas on the cat will be killed. However, re-infestation from the emergence of pre-existing pupae in the environment may continue to occur for six weeks or longer after treatment is initiated. Cats treated with imidacloprid, including those with pre-existing flea allergy dermatitis have shown clinical improvement as a direct result of elimination of fleas from the cat. Ear Mite Treatment: For the treatment of ear mites (Otodectes cynotis), PARASEDGE™ Multi for Cats should be administered once as a single topical dose. Monthly use of PARASEDGE™ Multi for Cats will control any subsequent ear mite infestations. Intestinal Nematode Treatment: For the treatment and control of intestinal hookworm infections caused by Ancylostoma tubaeforme (adults, immature adults and fourth stage larvae) and roundworm infections caused by Toxocara cati (adults and fourth stage larvae), PARASEDGE™ Multi for Cats should be administered once as a single topical dose.

TOPICAL

PARASEDGE™ Multi for Cats(imidacloprid + moxidectin)Topical Solution

The recommended minimum dose is 4.5 mg/lb (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin, once a month, by topical administration. Do not apply to irritated skin. 1.Remove one dose applicator tube from the package. As specified in the following table, administer the entire contents of the Advantage Multi for Dogs tube that correctly corresponds with the body weight of the dog. * Dogs over 110 lbs. should be treated with the appropriate combination of Advantage Multi for Dogs tubes. Dog (lbs.) Advantage Multi For Dogs Volume (mL) Imidacloprid (mg) Moxidectin (mg) 3–9 Advantage Multi 9 0.4 40 10 9.1–20 Advantage Multi 20 1.0 100 25 20.1–55 Advantage Multi 55 2.5 250 62.5 55.1–88 Advantage Multi 88 4.0 400 100 88.1–110* Advantage Multi 110 5.0 500 125 2.While holding the tube in an upright position, remove the cap from the tube. 3.Turn the cap over and push the other end of cap onto the tip of the tube. 4.Twist the cap to break the seal and then remove cap from the tube. 5.The dog should be standing for application. Part the hair on the back of the dog between the shoulder blades until the skin is visible. For dogs weighing 20 lbs. or less, place the tip of the tube on the skin and apply the entire contents directly on the exposed skin at one spot between the shoulder blades. For dogs weighing more than 20 lbs., place the tip of the tube on the skin and apply the entire contents directly on the exposed skin at 3 or 4 spots on the top of the backline from the base of the neck to the upper back in an area inaccessible to licking. Do not apply an amount of solution at any one location that could run off the side of the dog. Do not let this product get in your dog's mouth or eyes. Do not allow the dog to lick any of the application sites for 30 minutes. In households with multiple pets, keep each treated dog separated from other treated dogs and other pets for 30 minutes after application to prevent licking the application sites. (See WARNINGS.) Contact with eyes can lead to eye irritation and corneal ulceration. If contact with eyes occurs, hold the dog’s eyelids open, flush thoroughly with water, and contact your veterinarian. Stiff hair, a damp appearance of the hair, pink skin, or a slight powdery residue may be observed at the application site on some animals. This is temporary and does not affect the safety and effectiveness of the product. Shampooing 90 minutes after treatment does not reduce the effectiveness of Advantage Multi for Dogs in the prevention of heartworm disease. Shampooing or water immersion 4 days after treatment will not reduce the effectiveness of Advantage Multi for Dogs in the treatment of flea infestations. However, shampooing as often as once weekly may reduce the effectiveness of the product against fleas.

TOPICAL

Elanco TM advantage multi™ for dogs (imidacloprid+moxidectin) Topical Solution

The recommended minimum dose is 4.5 mg/lb (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin, once a month, by topical administration. Do not apply to irritated skin. Remove the applicator from the outer pouch using scissors or fold along diagonal line to expose nick; tear back at nick. As specified in the following table, administer the entire contents of the Midamox for Dogs (imidacloprid and moxidectin) applicator that correctly corresponds with the body weight of the dog. * Dogs over 110 lbs. should be treated with the appropriate combination of Midamox for Dogs applicators. Dog (lbs.) Midamox for Dogs Volume (mL) Imidacloprid (mg) Moxidectin (mg) 3–9 Midamox 9 0.4 40 10 9.1–20 Midamox 20 1.0 100 25 20.1–55 Midamox 55 2.5 250 62.5 55.1–88 Midamox 88 4.0 400 100 88.1–110* Midamox 110 5.0 500 125 Hold the applicator upright. Tap the narrow part of the applicator to ensure the contents remain within the main body of the applicator. Twist or snap back the tip. The dog should be standing for application. Part the hair on the back of the dog between the shoulder blades until the skin is visible. For dogs weighing 20 lbs. or less, place the tip of the applicator on the skin and apply the entire contents directly on the exposed skin at one spot between the shoulder blades. For dogs weighing more than 20 lbs., place the tip of the applicator on the skin and apply the entire contents directly on the exposed skin at 3 or 4 spots on the top of the backline from the base of the neck to the upper back in an area inaccessible to licking. Do not apply an amount of solution at any one location that could run off the side of the dog. Do not let this product get in your dog's mouth or eyes. Do not allow the dog to lick any of the application sites for 30 minutes. In households with multiple pets, keep each treated dog separated from other treated dogs and other pets for 30 minutes after application to prevent licking the application sites. (See WARNINGS.) Contact with eyes can lead to eye irritation and corneal ulceration. If contact with eyes occurs, hold the dog's eyelids open, flush thoroughly with water, and contact your veterinarian. Stiff hair, a damp appearance of the hair, pink skin, or a slight powdery residue may be observed at the application site on some animals. This is temporary and does not affect the safety and effectiveness of the product. Shampooing 90 minutes after treatment does not reduce the effectiveness of Midamox for Dogs in the prevention of heartworm disease. Shampooing or water immersion 4 days after treatment will not reduce the effectiveness of Midamox for Dogs in the treatment of flea infestations. However, shampooing as often as once weekly may reduce the effectiveness of the product against fleas.

TOPICAL

VETone ® Midamox ® for Dogs (imidacloprid + moxidectin)

The recommended minimum dose is 4.5 mg/lb (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin, once a month, by topical administration. Do not apply to irritated skin. 1. Remove one dose applicator tube from the package. As specified in the following table, administer the entire contents of the IMOXI™ Topical Solution for Dogs tube that correctly corresponds with the body weight of the dog. Dog (lbs.) Volume (mL) Imidacloprid (mg) Moxidectin (mg) 3–9 0.4 40 10 9.1–20 1.0 100 25 20.1–55 2.5 250 62.5 55.1–88 4.0 400 100 88.1–110 Dogs over 110 lbs. should be treated with the appropriate combination of IMOXI™ Topical Solution for Dogs tubes. 5.0 500 125 2. While holding the Twist•N•Go™ tube in an upright position, twist the dispensing cap clockwise about ½ turn to break the tube's seal. Remove the cap from the tube. 3. The dog should be standing for application. Position the dispensing tip on the dog's back between the shoulder blades. The dispensing tip of the tube can be used to part the dog's hair until the skin is visible. 4. For dogs weighing 20 lbs. or less, place the tip of the tube on the skin and apply the entire contents directly on the exposed skin at one spot between the shoulder blades. For dogs weighing more than 20 lbs., place the tip of the tube on the skin and apply the entire contents directly on the exposed skin at 3 or 4 spots on the top of the backline from the base of the neck to the upper back in an area inaccessible to licking. Do not apply an amount of solution at any one location that could run off the side of the dog. Do not let this product get in your dog's mouth or eyes. Do not allow the dog to lick any of the application sites for 30 minutes. In households with multiple pets, keep each treated dog separated from other treated dogs and other pets for 30 minutes after application to prevent licking the application sites. (See WARNINGS) Contact with eyes can lead to eye irritation and corneal ulceration. If contact with eyes occurs, hold the dog's eyelids open, flush thoroughly with water, and contact your veterinarian. Stiff hair, a damp appearance of the hair, pink skin, or a slight powdery residue may be observed at the application site on some animals. This is temporary and does not affect the safety and effectiveness of the product. Shampooing 90 minutes after treatment does not reduce the effectiveness of IMOXI™ Topical Solution for Dogs in the prevention of heartworm disease. Shampooing or water immersion 4 days after treatment will not reduce the effectiveness of IMOXI™ Topical Solution for Dogs in the treatment of flea infestations. However, shampooing as often as once weekly may reduce the effectiveness of the product against fleas.

TOPICAL

IMOXI™ Topical Solution for Dogs (imidacloprid + moxidectin)

The recommended minimum dose is 4.5 mg/lb (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin, once a month, by topical administration. Do not apply to irritated skin. Remove one dose applicator tube from the package. As specified in the following table, administer the entire contents of the Barrier for Dogs (imidacloprid + moxidectin) tube that correctly corresponds with the body weight of the dog. * Dogs over 110 lbs. should be treated with the appropriate combination of Barrier for Dogs tubes. Dog (lbs.) Volume (mL) Imidacloprid (mg) Moxidectin (mg) 3–9 0.4 40 10 9.1–20 1.0 100 25 20.1–55 2.5 250 62.5 55.1–88 4.0 400 100 88.1–110* 5.0 500 125 While holding the tube in an upright position, twist the cap to break the seal and apply. The cap will remain on the tube. 3. The dog should be standing for application. Part the hair on the back of the dog between the shoulder blades until the skin is visible. For dogs weighing 20 lbs. or less, place the tip of the tube on the skin and apply the entire contents directly on the exposed skin at one spot between the shoulder blades. For dogs weighing more than 20 lbs., place the tip of the tube on the skin and apply the entire contents directly on the exposed skin at 3 or 4 spots on the top of the backline from the base of the neck to the upper back in an area inaccessible to licking. Do not apply an amount of solution at any one location that could run off the side of the dog. Do not let this product get in your dog's mouth or eyes. Do not allow the dog to lick any of the application sites for 30 minutes. In households with multiple pets, keep each treated dog separated from other treated dogs and other pets for 30 minutes after application to prevent licking the application sites. (See WARNINGS.) Stiff hair, a damp appearance of the hair, pink skin, or a slight powdery residue may be observed at the application site on some animals. This is temporary and does not affect the safety and effectiveness of the product. Shampooing 90 minutes after treatment does not reduce the effectiveness of Barrier for Dogs in the prevention of heartworm disease. Shampooing or water immersion 4 days after treatment will not reduce the effectiveness of Barrier for Dogs in the treatment of flea infestations. However, shampooing as often as once weekly may reduce the effectiveness of the product against fleas.

TOPICAL

Barrier® for Dogs(imidacloprid+moxidectin)Topical Solution

The recommended minimum dose is 4.5 mg/lb (10.0 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin, once a month, by topical administration. Do not apply to irritated skin. 1. Remove one dose applicator tube from the package. As specified in the following table, administer the entire contents of the Barrier for Cats tube that correctly corresponds with the body weight of the cat. * Cats over 18 lbs. should be treated with the appropriate combination of Barrier for Cats tubes. Cat (lbs.) Volume (mL) Imidacloprid (mg) Moxidectin (mg) 2–5 0.23 23 2.3 5.1–9 0.4 40 4 9.1–18* 0.8 80 8 2. While holding the tube in an upright position, twist the cap to break the seal and then apply. The cap will remain on the tube.3.Part the hair on the back of the cat’s neck at the base of the head, until the skin is visible. Place the tip of the tube on the skin and apply the entire contents directly on the exposed skin. Lift tube away from skin before releasing pressure on tube. 3. Part the hair on the back of the cat’s neck at the base of the head, until the skin is visible. Place the tip of the tube on the skin and apply the entire contents directly on the exposed skin. Lift tube away from skin before releasing pressure on tube. Do not get this product in the cat's mouth or eyes or allow the cat to lick the application site for 30 minutes. Treatment at the base of the head will minimize the opportunity for ingestion by grooming. In households with multiple pets, keep animals separated to prevent licking of the application site. Stiff, matted hair or a damp, oily appearance of the hair may be observed at the application site on some cats. This is temporary and does not affect the safety and effectiveness of the product.

TOPICAL

Barrier® for Cats (imidacloprid+moxidectin) Topical Solution

The recommended minimum dose is 4.5 mg/lb (10.0 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin, once a month, by topical administration. Do not apply to irritated skin. 1. Remove the applicator from the outer pouch using scissors or fold along diagonal line to expose nick; tear back at nick. As specified in the following table, administer the entire contents of the Midamox for Cats (imidacloprid and moxidectin) applicator that correctly corresponds with the body weight of the cat. * Cats over 18 lbs. should be treated with the appropriate combination of Midamox for Cats applicators. Cat (lbs.) Midamox for Cats Volume (mL) Imidacloprid (mg) Moxidectin (mg) 2–5 Midamox 5 0.23 23 2.3 5.1–9 Midamox 9 0.4 40 4 9.1–18* Midamox 18 0.8 80 8 Hold the applicator upright. Tap the narrow part of the applicator to ensure the contents remain within the main body of the applicator. Twist or snap back the tip. Part the hair on the back of the cat's neck at the base of the head in front of the shoulder blades, until the skin is visible. Place the tip of the applicator on the skin and squeeze the applicator several times to empty its contents completely and directly onto the skin in one spot. Do not get this product in the cat's mouth or eyes or allow the cat to lick the application site for 30 minutes. Treatment at the base of the head will minimize the opportunity for ingestion by grooming. In households with multiple pets, keep animals separated to prevent licking of the application site. Stiff, matted hair or a damp, oily appearance of the hair may be observed at the application site on some cats. This is temporary and does not affect the safety and effectiveness of the product.

TOPICAL

VETone®Midamox ® for Cats (imidacloprid + moxidectin)

The recommended minimum dose is 4.5 mg/lb (10.0 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin, once a month, by topical administration. Do not apply to irritated skin. 1.Remove one dose applicator tube from the package. As specified in the following table, administer the entire contents of the Advantage Multi for Cats tube that correctly corresponds with the body weight of the cat. * Cats over 18 lbs. should be treated with the appropriate combination of Advantage Multi for Cats tubes. Cat (lbs.) Advantage Multi For Cats Volume (mL) Imidacloprid (mg) Moxidectin (mg) 2–5 Advantage Multi 5 0.23 23 2.3 5.1–9 Advantage Multi 9 0.4 40 4 9.1–18* Advantage Multi 18 0.8 80 8 2.While holding the tube in an upright position, remove the cap from the tube. 3.Turn the cap over and push the other end of cap onto the tip of the tube. 4.Twist the cap to break the seal and then remove cap from the tube. 5.Part the hair on the back of the cat's neck at the base of the head, until the skin is visible. Place the tip of the tube on the skin and apply the entire contents directly on the exposed skin. Lift tube away from skin before releasing pressure on tube. Do not get this product in the cat's mouth or eyes or allow the cat to lick the application site for 30 minutes. Treatment at the base of the head will minimize the opportunity for ingestion by grooming. In households with multiple pets, keep animals separated to prevent licking of the application site. Stiff, matted hair or a damp, oily appearance of the hair may be observed at the application site on some cats. This is temporary and does not affect the safety and effectiveness of the product.

TOPICAL

Elanco TM advantage multi™ for cats (imidacloprid+moxidectin) Topical Solution

DOSAGE AND ADMINISTRATION: The recommended minimum dose is 4.5 mg/lb (10.0 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin, once a month, by topical administration. Do not apply to irritated skin. 1. Remove one dose applicator tube from the package. As specified in the following table, administer the entire contents of the IMOXI™ Topical Solution for Cats tube that correctly corresponds with the body weight of the cat. Cat (lbs.) Volume (mL) Imidacloprid (mg) Moxidectin (mg) 2-5 0.23 23 2.3 5.1-9 0.4 40 4 9.1-18Cats over 18 lbs. should be treated with the appropriate combination of IMOXI™ Topical Solution for Cats tubes. 0.8 80 8 2. While holding the Twist•N•Go™ tube in an upright position, twist dispensing tip clockwise about ½ turn to break the tube's seal. Remove the cap from the tube. 3. Part the hair on the back of the cat's neck at the base of the head, until the skin is visible. 4. Place the tip of the tube on the skin and apply the entire contents directly on the exposed skin. Lift the tube away from the skin before releasing pressure on the tube. Do not get this product in the cat's mouth or eyes or allow the cat to lick the application site for 30 minutes. Treatment at the base of the head will minimize the opportunity for ingestion by grooming. In households with multiple pets, keep animals separated to prevent licking of the application site. Stiff, matted hair or a damp, oily appearance of the hair may be observed at the application site on some cats. This is temporary and does not affect the safety and effectiveness of the product.

TOPICAL

IMOXI™ Topical Solution for Cats (imidacloprid + moxidectin)

For ferrets: The recommended minimum dose for a ferret is 9 mg/lb (20 mg/kg) imidacloprid and 0.9 mg/lb (2 mg/kg) moxidectin, once a month, by topical administration. Heartworm Prevention: For prevention of heartworm disease, PARASEDGE Multi for Cats should be administered at one-month intervals. PARASEDGE Multi for Cats may be administered year-round or at a minimum should start one month before the first expected exposure to mosquitoes and should continue at monthly intervals until one month after the last exposure to mosquitoes. If a dose is missed and a 30-day interval between doses is exceeded, administer PARASEDGE Multi for Cats immediately and resume the monthly dosing schedule. Flea Treatment: For the treatment of flea infestations on ferrets, PARASEDGE Multi for Cats should be administered at one-month intervals. If the ferret is already infested with fleas when the first dose of PARASEDGE Multi for Cats is administered, adult fleas on the ferret will be killed. However, re-infestation from the emergence of pre-existing pupae in the environment may continue to occur for six weeks or longer after treatment is initiated.

TOPICAL

PARASEDGE™ Multi for Cats(imidacloprid + moxidectin)Topical Solution

You should weigh your dog before giving this medication to make sure you are using the right size for your dog. Do not give to puppies younger than 10 weeks of age or to dogs weighing less than 4 pounds. Do not give more than one tablet a day. Use the table to find the right dose for your dog: *If your dog becomes re-infested, you can safely repeat treatment as often as once a day. Dosing Table Body Weight Dose* Soft Chew Strength 4-22 lbs One Soft Chew 7.5 mg imidacloprid 23-110 lbs One Soft Chew 37.5 mg imidacloprid To give advantus, place the soft chew directly in your dog’s mouth or allow your dog to take the soft chew from your hand. Watch closely to ensure your dog swallows the soft chew. A single dose kills adult fleas on your dog. Because advantus does not have an effect on fleas in the environment, your dog may become re-infested with fleas. If your dog becomes re-infested, you can safely repeat treatment as often as once a day. Contact your veterinarian if you have any questions about flea infestations on your dog. Treat all pets in your household with a flea protection product. advantus should only be given to dogs.

ORAL

advantusTM (imidacloprid) soft chew